Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.22 which represents a slight increase of $0.38 or 0.42% from the prior close of $89.84. The stock opened at ...

GILD's full-year Zacks Consensus Estimates ... these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Gilead is expected to post earnings of $1.62 ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Gilead is expected to ...

If an investor was to purchase shares of GILD stock at the current price level of $89.05/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.